Eton Pharmaceuticals stock
ETONNASDAQEton Pharmaceuticals, Inc., HealthcareISIN US29772L1089
69Score 69 out of 100, Neutral
Price and trend
81 / 100
Price history
+252% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 63% above it.
Since March 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is 10% below its 52-week high. Largest decline in 8 years: 80% (February 2021 to October 2022).
Chart figures for advanced users
- SMA 50$55.18
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$37.61
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$14.35
- The lowest closing price of the last twelve months.
- Resistance$68.40
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Eton Pharmaceuticals, Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $1.77B, is number 54 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $79.95M (up 104.9% year on year) and a loss of $4.6M.
- For fiscal 2026, analysts expect on average revenue of $149.71M (up 87.3%) and adjusted earnings per share of $1.09.
Show more
- MEQIRI Score 69 out of 100 (Neutral): rank 158 of 714 in Healthcare, median 53.
- Our model puts fair value at $83.25, with the price 18% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Growing faster than its industryRevenue up 359.6% a year since 2020, Drug Manufacturers (Specialty & Generic) median 8.7%.Growth 70
- Analysts expect strong earnings growthUp 46.8% a year through 2028 (estimates from 4 analysts).Growth 70
- High marginNet margin 35.3% over the last 12 months, Drug Manufacturers (Specialty & Generic) median 8.6%.Profitability 99
Weaknesses
- Interest barely coveredOperating profit covers interest only 0 times.Stability 38
- DilutionShare count up 28% since 2020.Capital allocation 54
- Volatile share priceVolatility 75% a year over the last 12 months.Stability 38
Its standout strengths are profitability and momentum, while stability holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price up very strongly over the past year
- high price swings
- weak fundamentals
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $55.50 and expensive above $166.50 (uncertainty very high, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $67.94, at 7.8% it would be $106.33.
Valuation metrics
From the cash-flow model alone; the profit includes one-off items, so there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 105% on the prior year. Revenue turned from negative at the start of the period to positive ($79.95M in the latest year).
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 53%, operating 0%, net −6%. Last 12 months: net 35%.
Debt & balance sheet
Fiscal 2025Debt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 18 Mar 2027in 126 days
- Last reported
- 5 Nov 2026EPS reported $0.50 (expected $0.31)above expectations
Analyst estimates
- Earnings per share
- $1.09−7.8%
- Revenue
- $149.71M0.0%
- Earnings per share
- $2.08−4.5%
- Revenue
- $220.38M+0.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +41.6%2026 revenue guidance raised to above $145 million (before above $120 million) and adjusted EBITDA margin to above 35% (before above 30%).
“Even after new incremental expenses related to the ASN-001 transaction, which I will discuss in detail shortly, we now expect our full-year adjusted EBITDA margin to exceed 35%, up from our prior guidance of greater than 30%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 13 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 6 insiders sold, $30.75M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Casamento Charles JSale
10 Nov 2026, Board
- Shares
- 80,555
- Price
- $66.35
- Value
- $5.35M
- Krempa DavidSale
6 Oct 2026, Chief Business Officer
- Shares
- 4,166
- Price
- $55.07
- Value
- $229,406
- Maier Paul VSale
28 Aug 2026, Board
- Shares
- 50,000
- Price
- $59.07
- Value
- $2.95M
Show 12 more
- Krempa DavidSale
24 Aug 2026, Chief Business Officer
- Shares
- 25,000
- Price
- $65.07
- Value
- $1.63M
- Brynjelsen SeanSale
20 Aug 2026, President & CEO
- Shares
- 91,022
- Price
- $60.70
- Value
- $5.53M
- Brynjelsen SeanSale
19 Aug 2026, President & CEO
- Shares
- 8,978
- Price
- $62.65
- Value
- $562,472
- Opaleye Management Inc.Sale
14 Jul 2026, Major holder
- Shares
- 28,315
- Price
- $37.54
- Value
- $1.06M
- Opaleye Management Inc.Sale
7 Jul 2026, Major holder
- Shares
- 26,685
- Price
- $38.37
- Value
- $1.02M
- Opaleye Management Inc.Sale
6 Jul 2026, Major holder
- Shares
- 10,000
- Price
- $38.00
- Value
- $380,000
- Opaleye Management Inc.Sale
2 Jul 2026, Major holder
- Shares
- 90,000
- Price
- $37.39
- Value
- $3.36M
- Adams Jennifer McKieSale
17 Jun 2026, Board
- Shares
- 50,000
- Price
- $32.48
- Value
- $1.62M
- Brynjelsen SeanSale
28 May 2026, President & CEO
- Shares
- 120,000
- Price
- $31.88
- Value
- $3.83M
- Krempa DavidSale
27 May 2026, Chief Business Officer
- Shares
- 19,679
- Price
- $31.47
- Value
- $619,375
- Krempa DavidSale
26 May 2026, Chief Business Officer
- Shares
- 37,524
- Price
- $31.49
- Value
- $1.18M
- Krempa DavidSale
22 May 2026, Chief Business Officer
- Shares
- 42,797
- Price
- $33.39
- Value
- $1.43M
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Eton Pharmaceuticals
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 69
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- PerrigoPRGO $2.3B48
- Trulieve CannabisTRLV $2.17B48
- Dermapharm HoldingDMP.DE $2.13B68
- FagronFAGR.BR $1.99B70
- AlvotechALVO $1.76B43
- Faes FarmaFAE.MC $1.73B71
- SupernusSUPN $1.72B62
- ANI PharmaceuticalsANIP $1.63B61
ETFs that hold Eton Pharmaceuticals
Held by 8 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.11% | 0.30% | €185.82M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.09% | 0.35% | €1.21B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.06% | 0.30% | €2.17B |
Show 4 more
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.06% | 0.30% | €4.22B |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.53B |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.00% | 0.25% | €175.89M |
| State Street SPDR MSCI All Country World Investable Market UCITS ETF (Acc)SPYI | 0.00% | 0.17% | €8.6B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 10 Nov 2026, previously Strong
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.